| Market Cap | 14.96M | P/E | - | EPS this Y | 54.10% | Ern Qtrly Grth | - |
| Income | -25.97M | Forward P/E | -0.81 | EPS next Y | 39.60% | 50D Avg Chg | -5.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -19.00% |
| Dividend | N/A | Price/Book | 0.65 | EPS next 5Y | - | 52W High Chg | -85.00% |
| Recommedations | 2.00 | Quick Ratio | 1.83 | Shares Outstanding | 2.31M | 52W Low Chg | 7.00% |
| Insider Own | 1.59% | ROA | -82.27% | Shares Float | 2.14M | Beta | 2.92 |
| Inst Own | 14.81% | ROE | -160.47% | Shares Shorted/Prior | 6.64K/33.56K | Price | 0.57 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 435,450 | Target Price | 76.25 |
| Oper. Margin | - | Earnings Date | May 2 | Volume | 149,309 | Change | 1.02% |
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| McKee Kelly T. Jr. | Chief Medical Office.. Chief Medical Officer | Sep 25 | Buy | 0.52 | 9,653 | 5,020 | 28,838 | 09/27/23 |
| Reynolds Mark | CFO CFO | Aug 18 | Buy | 0.5179 | 10,000 | 5,179 | 78,184 | 08/21/23 |
| CHASE RANDAL D | Director Director | Sep 21 | Buy | 1.10 | 10,000 | 11,000 | 36,613 | 09/23/22 |
| McKee Kelly T. Jr. | Chief Medical Office.. Chief Medical Officer | Jun 27 | Buy | 1.12 | 4,464 | 5,000 | 19,185 | 06/28/22 |
| CHASE RANDAL D | Director Director | Jun 21 | Buy | 1.21 | 10,000 | 12,100 | 26,613 | 06/22/22 |
| McKee Kelly T. Jr. | Chief Medical Office.. Chief Medical Officer | May 05 | Buy | 0.72 | 9,722 | 7,000 | 14,721 | 05/06/22 |